List of Publications by Year in descending order

53 papers	13,190 citations	117453 34 h-index	168136 53 g-index
53 all docs	53 docs citations	53 times ranked	17417 citing authors

#	Article	IF	Citations
1	Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. Cell Death and Disease, 2022, 13, 274.	2.7	11
2	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Molecular Medicine, 2021, 13, e13144.	3.3	13
3	Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53. Oncogene, 2021, 40, 3665-3679.	2.6	8
4	Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2021, 81, 3862-3875.	0.4	3
5	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	2.7	191
6	TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	57
7	TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Science Signaling, 2021, 14, .	1.6	7
8	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748.	1.7	148
9	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	13.5	691
10	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 2020, 12, 2394.	1.7	34
11	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	1.9	32
12	ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports, 2019, 29, 104-117.e4.	2.9	16
13	Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochemical and Biophysical Research Communications, 2019, 513, 219-225.	1.0	4
14	The circ<scp>RNA</scp>â€“micro<scp>RNA</scp> code: emerging implications for cancer diagnosis and treatment. Molecular Oncology, 2019, 13, 669-680.	2.1	300
15	Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology, 2019, 1904, 11-51.	0.4	25
16	SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling, 2018, 11, .	1.6	41
17	An oligoclonal antibody durably overcomes resistance of lung cancer to thirdâ€generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.	3.3	46
18	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research, 2018, 24, 5610-5621.	3.2	43

#	Article	IF	Citations
19	Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6410-6415.	3.3	81
20	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ€cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	2.7	56
21	An antibody to amphiregulin, an abundant growth factor in patientsâ€™ fluids, inhibits ovarian tumors. Oncogene, 2016, 35, 438-447.	2.6	33
22	Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Research, 2016, 44, 1370-1383.	6.5	484
23	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	2.3	31
24	Navigatorâ€3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Molecular Medicine, 2015, 7, 299-314.	3.3	34
25	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling, 2015, 8, ra53.	1.6	33
26	Examination of HER3 targeting in cancer using monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 839-844.	3.3	45
27	Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling, 2015, 8, ra7.	1.6	53
28	EGF receptor family: twisting targets for improved cancer therapies. Growth Factors, 2014, 32, 74-81.	0.5	10
29	Structure and function of epigen, the last EGFR ligand. Seminars in Cell and Developmental Biology, 2014, 28, 57-61.	2.3	30
30	Steering tumor progression through the transcriptional response to growth factors and stroma. FEBS Letters, 2014, 588, 2407-2414.	1.3	7
31	Endocytosis and Cancer. Cold Spring Harbor Perspectives in Biology, 2013, 5, a016949-a016949.	2.3	314
32	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1815-1820.	3.3	98
33	Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15389-15394.	3.3	40
34	A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene, 2012, 31, 3505-3515.	2.6	28
35	EGR1 and the ERKâ€ERF axis drive mammary cell migration in response to EGF. FASEB Journal, 2012, 26, 1582-1592.	0.2	88
36	The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer, 2012, 12, 553-563.	12.8	766

#	Article	IF	Citations
37	Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Molecular Cell, 2011, 42, 524-535.	4.5	93
38	Coupled preâ€mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Molecular Systems Biology, 2011, 7, 529.	3.2	126
39	Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Reviews Molecular Cell Biology, 2011, 12, 104-117.	16.1	597
40	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13252-13257.	3.3	135
41	Roles for Growth Factors in Cancer Progression. Physiology, 2010, 25, 85-101.	1.6	342
42	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	1.6	100
43	Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12559-12563.	3.3	22
44	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3294-3299.	3.3	161
45	Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology, 2007, 1, 42-54.	2.1	48
46	A module of negative feedback regulators defines growth factor signaling. Nature Genetics, 2007, 39, 503-512.	9.4	506
47	Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity. Journal of Biological Chemistry, 2005, 280, 8503-8512.	1.6	83
48	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1915-1920.	3.3	225
49	Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001, 2, 127-137.	16.1	5,977
50	The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4995-5000.	3.3	396
51	Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO Journal, 1998, 17, 5948-5963.	3.5	109
52	Epiregulin Is a Potent Pan-ErbB Ligand That Preferentially Activates Heterodimeric Receptor Complexes. Journal of Biological Chemistry, 1998, 273, 10496-10505.	1.6	141
53	Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 1990, 29, 11024-11028.	1.2	228